NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

CompletedPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Muscular Atrophy, Spinal

Interventions: Risdiplam

Countries: United States, Belgium, Canada, Germany, Italy, Netherlands, Norway, Poland

This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.

Eligibility overview

Sex: ALL

Age: — to 19 Days

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female newborn infant aged \<20 days at first dose
* Newborn infants with genetic diagnosis of 5q-autosomal recessive SMA or newborn infants identified as positive for SMA via newborn screening or via prenatal testing.
* Gestational age equal to or greater than 37 weeks
* Receiving adequate nutrition and hydration at the time of screening
* Adequately recovered from any acute illness at baseline and considered well enough to participate in the study
* Parent/caregiver is willing to consider nasogastric, nasojejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator.

Exclusion Criteria:

* Presence of clinical symptoms or signs consistent with SMA Type 0
* In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
* Systolic blood pressure or diastolic blood pressure or heart rate abnormalities
* Presence of clinically relevant electrocardiogram (ECG) abnormalities
* The infant (or the person breastfeeding the infant) taking any of the following: any inhibitor of CYP3A4 taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing, any inducer of CYP3A4 taken within 4 weeks (or within 5 times the elimination half-life, whichever is longer prior to dosing, and/or use of any multidrug and toxin extrusion (MATE) substrates taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing
* Concurrent or previous administration of nusinersen or onasemnogene abeparvovec
* Clinically significant abnormalities in laboratory test

Locations (13)

Chicago, Illinois, United States
Ann Arbor, Michigan, United States
Gordonville, Pennsylvania, United States
Brussels, Belgium
Liège, Belgium
Ottawa, Ontario, Canada
Essen, Germany
Milano, Emilia-Romagna, Italy
ROMA, Emilia-Romagna, Italy
Utrecht, Netherlands
Oslo, Norway
Gdansk, Poland
Warsaw, Poland